- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00402649
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
June 9, 2011 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
Open-Label Study of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years to 10 Years
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study.
Participants will include 55 healthy children, ages 2-10, who participated in 04-077 and received a placebo injection instead of the flu vaccine or were incompletely immunized.
The study has 2 purposes: to make sure there are no serious side effects in children and to see how the immune systems react to the vaccine.
Study procedures include up to 4 study visits, up to 9 follow-up phone calls, 2 blood samples to be collected during visits 1 and 3, and up to 3 vaccine injections in the arm or thigh muscle.
Parents will be given a memory aid card to record side effects, temperatures, and medications.
Parents will have the option for the child to receive a 3rd dose of vaccine if offered, at month 6.
This booster shot will require a 6-month visit and participation for an additional 6 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The recent emergence of novel influenza virus strains in human populations has encouraged efforts to develop vaccines for a potential pandemic.
The objectives of this study are to evaluate the safety of intramuscular (IM) subvirion inactivated H5N1 vaccine in healthy children aged 2 through 10 years and to determine the immunogenicity profile of IM subvirion inactivated H5N1 vaccine in healthy children approximately 1 month following receipt of the second of 2 doses of vaccine.
Study endpoints include: adverse event (AE) and serious adverse event (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessments, as indicated); proportion of subjects achieving a serum hemagglutination inhibition antibody titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of second dose of vaccine (approximately Day 56); geometric mean titer and the frequency of 4-fold or greater increases in hemagglutination inhibition antibody titers 28 days after receipt of second dose of vaccine (approximately Day 56); and development of serum antibody responses against antigenically drifted variants of influenza H5N1 virus.
This study is linked to DMID protocol 06-0072.
Up to 55 healthy children, aged 2 through 10 years, who previously participated in DMID 04-077, will be eligible for enrollment in this multimember, open-label, phase I/II clinical trial to receive at least 2 and up to 3 doses of an inactivated influenza A/H5N1 vaccine at a 45-micrograms dose.
The vaccine dosage level that will be used in this study was chosen based upon safety and immunogenicity data collected previously in adults and children.
The injection volume of the 90-micrograms dose is 1 mL for the vaccine being used in this study, but this is considered unacceptable in this age group.
Therefore, the 45-micrograms dose (0.5 ml volume) has been selected.
Twenty three subjects who were previously enrolled and assigned to placebo in the DMID 04-077 study (A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years) along with up to 32 subjects from a single site who were incompletely immunized are eligible for enrollment in this study.
Vaccine will be administered into the deltoid or (if age appropriate) thigh muscle.
All subjects will receive 2 doses of the vaccine approximately 28 days apart.
At month 6, subjects' parent(s) or guardian(s) will be called to assess the subjects for serious adverse events.
Blood collection for immunogenicity studies will be at the discretion of the parent(s) or legal guardian(s).
Should data evaluating a third dose of the influenza A/H5N1 vaccine show enhanced immunogenicity in pediatric subjects participating in DMID 04-077, parents/guardians of subjects who received vaccine will be offered the possibility of a third dose for their participating children.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Torrance, California, United States, 90502
- UCLA Center for Vaccine Research
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Baltimore
-
-
Missouri
-
St. Louis, Missouri, United States, 63104
- Saint Louis University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject must be male or female, aged 2 through 10 years at enrollment, and must have participated in protocol 04-077 as a placebo recipient or a subject at the UCLA site.
- The subject must be in good health (and not on any chronic medications), as determined by medical history and a history-directed targeted physical examination.
- Parents or guardians of the subject must be able to understand and comply with planned study procedures and be available for all study visits.
- Parents or guardians of the subject must provide written consent prior to initiation of any study procedures, and subject may provide written assent as appropriate.
Exclusion Criteria:
- The subject must not have a known allergy to eggs or other components of the vaccine or sensitivity or allergy to latex.
- The subject must not have a history of asthma or recurrent wheezing.
- The subject must not be undergoing immunosuppression as a result of an underlying illness or treatment.
- The subject must not have an active neoplastic disease or a history of any hematologic malignancy.
- The subject must not be using oral or parenteral steroids, inhaled steroids, or other immunosuppressive or cytotoxic drugs. Note: Subjects on nasal or topical steroids will be allowed to enroll in this study.
- The subject must not have a history of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study.
- The subject must not receive any other inactivated vaccines within 2 weeks before or after any study vaccine or any other live vaccines within 4 weeks before or after any study vaccine in this study.
- The subject must not have an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses (these conditions include, but are not limited to, known chronic liver disease, significant renal disease, unstable or progressive neurological disorders, diabetes mellitus, and transplant recipients).
- The subject must not have a history of severe reactions following immunization with contemporary influenza virus vaccines.
- The subject must not have an acute illness, including an axillary temperature greater than or equal to 100 degrees F or an oral temperature greater than or equal to 101 degrees F within 3 days prior to vaccination.
- The subject must not have received an experimental vaccine or medication within 1 month prior to enrollment in this study, or expect to receive an experimental vaccine, medication, or blood product during the 13-month study period.
- The subject must not have any condition that would, in the opinion of the investigator, place them at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
- The subject must not have a history of Guillain-Barré syndrome.
- The subject must not be participating concurrently in another clinical trial aside from DMID 04-077 (either in active phase or in follow-up phase).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
|
Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Solicited Adverse Events Among All Subjects
Time Frame: Days 0-7 post each vaccination
|
Number of subjects reporting solicited Adverse Events collected on Memory Aid for Days 0-7 post each vaccination for all subjects (systematic assessment), for any and severe severities.
|
Days 0-7 post each vaccination
|
Occurrence of the Solicited Adverse Event of Body Aches, Solicited Only From Children Age 6-10
Time Frame: Days 0-7 post each vaccination
|
Number of subjects reporting solicited Adverse Event of Body Aches, collected on Memory Aid for Days 0-7 post each vaccination for children age 6-10 only (systematic assessment), of any and severe severities.
|
Days 0-7 post each vaccination
|
Occurrence of Unsolicited Adverse Events
Time Frame: Through Day 28 after second vaccination
|
Number of subjects with spontaneous reports of Adverse Events of any and severe severities.
Events reported by more than 5.6% of subjects in any group are reported by MedDRA Preferred Term.
|
Through Day 28 after second vaccination
|
Occurrence of Serious Adverse Events
Time Frame: 6 months after the first vaccination
|
Number of subjects with Serious Adverse Events during the 6 months after the first vaccination.
|
6 months after the first vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Titers of 1:40 or Greater
Time Frame: Day 28 after second vaccination
|
Number of subjects achieving serum hemagglutination inhibition antibody titer of 1:40 or greater against the influenza A/H5N1 virus after receipt of two doses of vaccine.
|
Day 28 after second vaccination
|
Geometric Mean Titer of Hemagglutination Inhibition Antibody Titers
Time Frame: Day 28 after second vaccination
|
Geometric mean titer of hemagglutination inhibition antibody titers after receipt of two doses of vaccine.
|
Day 28 after second vaccination
|
Number of Participants With a Four-fold or Greater Increase in Hemagglutination Inhibition Antibody Titers
Time Frame: Day 28 after second vaccination
|
Number of subjects with a 4-fold or greater increase, relative to baseline, in hemagglutination inhibition antibody titers after receipt of two doses of vaccine.
|
Day 28 after second vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
November 21, 2006
First Submitted That Met QC Criteria
November 21, 2006
First Posted (Estimate)
November 22, 2006
Study Record Updates
Last Update Posted (Estimate)
June 13, 2011
Last Update Submitted That Met QC Criteria
June 9, 2011
Last Verified
May 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-0072
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Emergent BioSolutionsCompletedInfluenza | Bird FluUnited States
-
The University of Hong KongResearch Grants Council, Hong Kong; Research Fund for the Control of Infectious... and other collaboratorsCompletedInfluenza Virus InfectionChina
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedInfluenza
-
Vanderbilt UniversityCenters for Disease Control and PreventionCompleted
-
Eastern Virginia Medical SchoolNanoPass Technologies LtdCompletedPolio ImmunityUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Centers for Disease Control and PreventionUnknown